Molecular biological subtypes of breast cancer in BRCA1 mutation carriers

Background. According to the literature, BRCA1-associated breast cancer (BC) most often belongs to the triple negative (TNBC) molecular subtype. The data on the contribution of other molecular subtypes to this group of patients differ among different studies.

The study objective is to evaluate the frequency of different tumor molecular subtypes in BC patients with BRCA1 gene mutation treated in N. N. Blokhin National Medical Research Center of Oncology in the period from 2017 to 2020.

Materials and methods. The study included BC patients with a mutation in the BRCA1 gene (n = 209) identified as a result BRCA1 mutation screening of patients with BC. DNA diagnostics was carried out on blood samples of patients using the real-time polymerase chain reaction method. After analyzing the patients primary documentation clinical and morphological data were taken into account: the age of diagnosis, the stage of the disease, the results of immunohistochemical studies (estrogen receptor status, progesterone receptor status, HER2 expression, Ki-67 proliferation index). The assignment to the particular molecular tumour subtypes was performed according to estrogen receptor status, progesterone receptor status, HER2 status and Ki67 value.

Results. Clinical and pathomorphological data of 209 patients with BRCA1-associated BC were analyzed. The age at diagnosis ranged from 23 to 72 years, the median age was 40 years, the mean age was 41.46 ± 9.82 years. BC associated with BRCA1 was found to be TNBC in 71.3 % and luminal B, HER2 negative (LumB–) in 19.1 % of the cases. Other tumour subtypes were much less common: luminal B, HER2 positive (LumB+) in 7.2 %, luminal A (LumA) in 1 % and HER2-positive (HER2+) in 1.4 % of the cases. The frequency of subtypes was estimated in different age groups (1st – patients 23–34 (n = 53), 2nd – 35–49 (n = 111), and 3rd – 50–72 (n = 45) years old). TNBC frequency was 81.1 % in the 1st group, 73.9 % in the 2nd and 53.4 % in the 3rd group; LumB– frequency was 15.1, 15.3 and 33.3 % respectively. Using the Fisher test it was shown that the differences in frequencies were statistically significant between groups 1st and 3 rd, as well as between groups 2 nd and 3 rd (p <0.05).

Conclusion. TNBC was the main molecular subtype in all age groups of BC patients with BRCA1 germinal mutation, TNBC frequency was lower in the older age group. LumB– subtype was also common in BRCA1-associated tumors especially in older women.

1. Lakhani S., Van De Vijver M., Jacquemier J. et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310–8. DOI: 10.1200/JCO.2002.09.023.

2. Atchley D., Albarracin C., Lopez A. et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008;26(26):4282–8. DOI: 10.1200/JCO.2008.16.6231.

3. El Tannouri R., Albuisson E., Jonveaux P., Luporsi E. Clinical and pathologic characteristics of breast cancer patients carrying the c.3481_3491del11 mutation. Familial Cancer 2019;18(1):1–8. DOI: 10.1007/s10689-018-0079-1.

4. Musolino A., Michiara M., Bella M. et al. Molecular profile and clinical variables in BRCA1-positive breast cancers: a population-based study. Tumori 2005;91(6):505–12.

5. Nielsen T., Jensen M., Burugu S. et al. High-risk premenopausal luminal A breast cancer patients derive no benefit from adjuvant cyclophosphamide-based chemotherapy: results from the DBCG77B clinical trial. Clin Cancer Res 2017;23:946–53. DOI: 10.1158/1078-0432.CCR-16-1278.

6. Sorlie T., Perou C., Tibshirani R. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869–74. DOI: 10.1073/pnas.191367098.

7. http://www.oncology.ru/association/clinical-guidelines/2018/rak_molochnoy_zhelezy_pr2018.pdf.

8. Mavaddat N., Barrowdale D., Andrulis I. et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2(CIMBA). Cancer Epidemiol Biomarkers Prev 2012;21(1):134–47. DOI: 10.1158/1055-9965.

9. Eerola H., Heikkila P., Tamminen A. et al. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation negative breast cancer families. Breast Cancer Res 2005;7(1):R93–100. DOI: 10.1186/bcr953.

10. Comen E., Davids M., Kirchhoff T. et al. Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi women. Breast Cancer Res Treat 2011;129(1):185–90. DOI: 10.1007/s10549-011-1433-2.

11. Haque R., Jiaxiao M., Telford C. et al. Survival outcomes in BRCA1 or BRCA2 mutation carriers and the influence of triple-negative breast cancer subtype. Perm J 2018;22:17–197. DOI: 10.7812/TPP/17-197.

12. Huszno J., Kolosza Z. Molecular characteristics of breast cancer according to clinicopathological factors. Mol Clin Oncol 2019;11(2):192–200. DOI: 10.3892/mco.2019.1869.

13. Sønderstrup I., Jensen M., Ejlertsen D. et al. Subtypes in BRCA-mutated breast cancer. Hum Pathol 2019;84:192–201. DOI: 10.1016/j.humpath.2018.10.005.

14. Talhouet S., Peron J., Vuilleumier A. et al. Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes. Sci Rep 2020;10(1):7073. DOI: 10.1038/s41598-020-63759-1.

15. Yoshida R., Watanabe C., Yokoyama S. et al. Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X. Oncotarget 2019;10(35):3276–84. DOI: 10.18632/oncotarget.26852.

16. Ivantsov A.O. Clinical and morphological features of BRCA1-associated tumors in humans. Author’s abstract dis. … Doctor of Medical Sciences. Saint-Petersburg, 2019. 50 p. (In Russ.).

17. Bit-Sava E.M. Molecular and biological justification for treatment of BRCA1/СНЕК2/BLM-associated and sporadic breast cancer. Author’s abstract dis. … Doctor of Medical Sciences. Saint-Petersburg, 2014. 48 p. (In Russ.).

18. Tung N., Wang Y., Collins L. et al. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res 2010;12:R12. DOI: 10.1186/bcr2478.

19. Foulkes W., Metcalfe K., Sun P. et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 2004;10:2029–34. DOI: 10.1158/1078-0432.ccr-03-1061.

20. Mulligan A., Couch F., Barrowdale D. et al. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res 2011;13(6):R110. DOI: 10.1186/bcr3052.

21. Tung N., Miron A., Schnitt S. et al. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Res 2010;12:R95. DOI: 10.1186/bcr2776.

22. Milne R., Antoniou A. Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers. Ann Oncol 2011;22(Suppl 1):i11–7. DOI: 10.1093/annonc/mdq660.

23. Lips E., Debipersad R., Scheerman C. et al. BRCA1-mutated estrogen receptor-positive breast cancer shows BRCAness, suggesting sensitivity to drugs targeting homologous recombination deficiency. Clin Cancer Res 2017;23(5):1236–41. DOI: 10.1158/1078-0432.CCR-16-0198.